General information

Announcements(0)

Greetings from the Chair

Overview

Web abstract

Registration

Information for Speakers, Presenters and Chairs

Program

Sessions

Search presentations

General information 2

Abstract Submission (Oral/Poster Presentation)

pharm143_en.png

icon_20251203182619268.png

Change account information such as the email address and password on the account setting screen common to Confit.

Login required to view

Password required to view

Presentation Information

Session Details

Enter the password to view the abstracts. The password will be emailed to those who have completed the registration.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Program Type

Announcements

Profile management

Bookmark

Download PDF for print

Timetable

Current status and future perspectives of radionuclide therapy with 177Lu

Radiopharmaceuticals are essential for diagnosis and therapy in nuclear medicine. With the approval of a drug for peptide receptor radionuclide therapy (177Lu-DOTATATE: Lutathera®) in Japan in 2021, therapy in nuclear medicine has been attracting a great deal of attention in recent years. As a result, the development of therapeutic radiopharmaceuticals has entered a new phase. In addition, developing many types of radiopharmaceuticals, such as small molecules, peptides, antibodies, and nanoparticles, is promoted. On the other hand, boron neutron capture therapy (BNCT), approved in 2020, is a cancer treatment method using Li nuclei and alpha particles generated by in vivo nuclear reaction to boron (10B) drugs accumulated in cancer by neutron irradiation. Naturally, BNCT needs drugs with 10B. Common to both therapies are "radiation and drugs," and great expectations are placed on pharmaceutical sciences, especially about drugs. In this symposium, we would like to discuss this field's current status and future prospects by inviting researchers conducting cutting-edge research in their respective fields as speakers.

How can we change medicine by radiation and pharmaceuticals?

The 143rd Annual Meeting of the Pharmaceutical Society of Japan (Sapporo)

Presentation Information

[S06-01]Current status and future perspectives of radionuclide therapy with ¹⁷⁷Lu

Password required to view

Presentation Information

[S06-01]Current status and future perspectives of radionuclide therapy with 177Lu

Password required to view

[S06-01]Current status and future perspectives of radionuclide therapy with ¹⁷⁷Lu